BIO Is Expanding Its Work to Defend IP

Why It Matters

Strong patent protection underpins biotech R&D financing and keeps the United States at the forefront of medical innovation, making it a strategic economic and security priority.

Key Takeaways

• BIO launches IP Task Force to coordinate member advocacy.
• New board committee will steer BIO’s IP strategy and policy.
• BIO opposes ETHIC Act, which could limit multiple drug patents.
• Amicus brief filed with Supreme Court supports Hatch‑Waxman balance.
• International comments target China’s IP practices in USTR Special 301 report.

Pulse Analysis

Biotech firms rely on patents to monetize years of research and billions in development costs. Recognizing this, BIO has broadened its IP advocacy infrastructure, adding an IP Task Force that brings together corporate lawyers, policy experts, and patient advocates. The newly formed Economic Growth, Innovation, and Intellectual Property Committee will set a cohesive agenda, ensuring that BIO’s lobbying, thought‑leadership reports, and public education campaigns are aligned and impactful.

On the policy front, BIO is confronting several legislative and judicial challenges. The organization has publicly opposed the proposed ETHIC Act, which would restrict multiple patents for a single drug, arguing that such limits could erode incentives for incremental innovations like new delivery methods. BIO also submitted an amicus brief to the Supreme Court, defending the Hatch‑Waxman framework that balances generic competition with innovation protection. In Congress, BIO’s statements before the Senate HELP Committee highlighted the importance of exclusivity periods and called for greater FDA transparency on biologic patents.

Beyond domestic battles, BIO is addressing global IP threats, especially from China. By commenting on the USTR’s Special 301 report, BIO stresses that forced technology transfers and weak enforcement undermine U.S. biotech leadership. The organization frames IP protection as a national‑security issue, linking it to trade policy, regulatory modernization, and access to life‑saving medicines. As BIO’s expanded efforts take shape, the biotech sector can expect a more coordinated defense of its intellectual assets, safeguarding both investor confidence and America’s competitive edge.